Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Authors
Keywords
-
Journal
npj Breast Cancer
Volume 8, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-29
DOI
10.1038/s41523-022-00467-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- (2021) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
- (2021) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
- (2020) David M. Goldenberg et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions
- (2020) Emaan Haque et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
- (2018) Alice Lee et al. CANCER TREATMENT REVIEWS
- Advances in the systemic treatment of triple-negative breast cancer
- (2018) J.M. Lebert et al. Current Oncology
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
- (2018) In Hae Park et al. Cancer Research and Treatment
- Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials
- (2018) Hope S. Rugo et al. Clinical Breast Cancer
- Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer
- (2017) Hope S. Rugo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer
- (2017) Julie Nangia et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Determining Chemotherapy Tolerance in Older Patients With Cancer
- (2017) Jerome Kim et al. Journal of the National Comprehensive Cancer Network
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Biology and Management of Patients With Triple-Negative Breast Cancer
- (2016) P. Sharma ONCOLOGIST
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2015) Peter A. Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
- (2015) Betsy A. Kohler et al. JNCI-Journal of the National Cancer Institute
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State
- (2015) Betsy A. Kohler et al. JNCI-Journal of the National Cancer Institute
- Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
- (2014) Chris Twelves et al. BREAST CANCER RESEARCH AND TREATMENT
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women
- (2014) E. O. Jenkins et al. ONCOLOGIST
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
- (2013) X Liu et al. PHARMACOGENOMICS JOURNAL
- Upregulation of Trop-2 quantitatively stimulates human cancer growth
- (2012) M Trerotola et al. ONCOGENE
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
- (2008) D M Kweekel et al. BRITISH JOURNAL OF CANCER
- Clinical and pharmacogenetic factors associated with irinotecan toxicity
- (2008) Dinemarie Kweekel et al. CANCER TREATMENT REVIEWS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now